Regulus Therapeutics (RGLS) Commences Dosing in RG-125(AZD4076) Phase 1 (AZN)
Tweet Send to a Friend
Regulus Therapeutics Inc. (NASDAQ: RGLS) announced that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
